Last reviewed · How we verify

Combination PD-1/PD-L1 ICI + VEGFR-TKI

University Hospital, Bordeaux · Phase 3 active Small molecule

Combination PD-1/PD-L1 ICI + VEGFR-TKI is a PD-1/PD-L1 inhibitor + VEGFR tyrosine kinase inhibitor combination Small molecule drug developed by University Hospital, Bordeaux. It is currently in Phase 3 development for Advanced or metastatic solid tumors (specific indication under investigation in phase 3).

This combination blocks PD-1/PD-L1 immune checkpoints to enhance T-cell anti-tumor activity while simultaneously inhibiting VEGFR tyrosine kinases to suppress tumor angiogenesis and promote anti-angiogenic immune effects.

This combination blocks PD-1/PD-L1 immune checkpoints to enhance T-cell anti-tumor activity while simultaneously inhibiting VEGFR tyrosine kinases to suppress tumor angiogenesis and promote anti-angiogenic immune effects. Used for Advanced or metastatic solid tumors (specific indication under investigation in phase 3).

At a glance

Generic nameCombination PD-1/PD-L1 ICI + VEGFR-TKI
SponsorUniversity Hospital, Bordeaux
Drug classPD-1/PD-L1 inhibitor + VEGFR tyrosine kinase inhibitor combination
TargetPD-1, PD-L1, VEGFR (vascular endothelial growth factor receptor)
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

PD-1/PD-L1 inhibitors release the brakes on T-cell-mediated immunity, allowing immune cells to attack cancer cells more effectively. VEGFR tyrosine kinase inhibitors block tumor blood vessel formation and have been shown to enhance immune infiltration into tumors. The combination leverages complementary mechanisms: immunotherapy plus anti-angiogenic therapy, which can improve response rates in solid tumors.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Combination PD-1/PD-L1 ICI + VEGFR-TKI

What is Combination PD-1/PD-L1 ICI + VEGFR-TKI?

Combination PD-1/PD-L1 ICI + VEGFR-TKI is a PD-1/PD-L1 inhibitor + VEGFR tyrosine kinase inhibitor combination drug developed by University Hospital, Bordeaux, indicated for Advanced or metastatic solid tumors (specific indication under investigation in phase 3).

How does Combination PD-1/PD-L1 ICI + VEGFR-TKI work?

This combination blocks PD-1/PD-L1 immune checkpoints to enhance T-cell anti-tumor activity while simultaneously inhibiting VEGFR tyrosine kinases to suppress tumor angiogenesis and promote anti-angiogenic immune effects.

What is Combination PD-1/PD-L1 ICI + VEGFR-TKI used for?

Combination PD-1/PD-L1 ICI + VEGFR-TKI is indicated for Advanced or metastatic solid tumors (specific indication under investigation in phase 3).

Who makes Combination PD-1/PD-L1 ICI + VEGFR-TKI?

Combination PD-1/PD-L1 ICI + VEGFR-TKI is developed by University Hospital, Bordeaux (see full University Hospital, Bordeaux pipeline at /company/university-hospital-bordeaux).

What drug class is Combination PD-1/PD-L1 ICI + VEGFR-TKI in?

Combination PD-1/PD-L1 ICI + VEGFR-TKI belongs to the PD-1/PD-L1 inhibitor + VEGFR tyrosine kinase inhibitor combination class. See all PD-1/PD-L1 inhibitor + VEGFR tyrosine kinase inhibitor combination drugs at /class/pd-1-pd-l1-inhibitor-vegfr-tyrosine-kinase-inhibitor-combination.

What development phase is Combination PD-1/PD-L1 ICI + VEGFR-TKI in?

Combination PD-1/PD-L1 ICI + VEGFR-TKI is in Phase 3.

What are the side effects of Combination PD-1/PD-L1 ICI + VEGFR-TKI?

Common side effects of Combination PD-1/PD-L1 ICI + VEGFR-TKI include Hypertension, Fatigue, Diarrhea, Immune-related adverse events (pneumonitis, hepatitis, colitis), Proteinuria, Hand-foot skin reaction.

What does Combination PD-1/PD-L1 ICI + VEGFR-TKI target?

Combination PD-1/PD-L1 ICI + VEGFR-TKI targets PD-1, PD-L1, VEGFR (vascular endothelial growth factor receptor) and is a PD-1/PD-L1 inhibitor + VEGFR tyrosine kinase inhibitor combination.

Related